CN1526391A - 含有5-［4-［2-(n-甲基-n-2-吡啶基)氨基)乙氧基］苄基］噻唑烷-2，4-二酮的组合物 - Google Patents
含有5-［4-［2-(n-甲基-n-2-吡啶基)氨基)乙氧基］苄基］噻唑烷-2，4-二酮的组合物 Download PDFInfo
- Publication number
- CN1526391A CN1526391A CNA2003101199090A CN200310119909A CN1526391A CN 1526391 A CN1526391 A CN 1526391A CN A2003101199090 A CNA2003101199090 A CN A2003101199090A CN 200310119909 A CN200310119909 A CN 200310119909A CN 1526391 A CN1526391 A CN 1526391A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- chemical compound
- compositions
- acceptable form
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 title claims description 8
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 title description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000003937 drug carrier Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 206010012601 diabetes mellitus Diseases 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 11
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 11
- 235000008504 concentrate Nutrition 0.000 description 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 239000008109 sodium starch glycolate Substances 0.000 description 7
- 229920003109 sodium starch glycolate Polymers 0.000 description 7
- 229940079832 sodium starch glycolate Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 229960001021 lactose monohydrate Drugs 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009501 film coating Methods 0.000 description 3
- 239000007888 film coating Substances 0.000 description 3
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000002278 tabletting lubricant Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000003799 water insoluble solvent Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9711683.4 | 1997-06-05 | ||
| GBGB9711683.4A GB9711683D0 (en) | 1997-06-05 | 1997-06-05 | Composition |
| GB9712851.6 | 1997-06-18 | ||
| GBGB9712851.6A GB9712851D0 (en) | 1997-06-18 | 1997-06-18 | Composition |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02149972A Division CN1430959A (zh) | 1997-06-05 | 2002-11-05 | 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1526391A true CN1526391A (zh) | 2004-09-08 |
Family
ID=26311662
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98805686A Expired - Lifetime CN1112926C (zh) | 1997-06-05 | 1998-06-02 | 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物 |
| CNA2003101199090A Pending CN1526391A (zh) | 1997-06-05 | 1998-06-02 | 含有5-［4-［2-(n-甲基-n-2-吡啶基)氨基)乙氧基］苄基］噻唑烷-2，4-二酮的组合物 |
| CN02149972A Pending CN1430959A (zh) | 1997-06-05 | 2002-11-05 | 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98805686A Expired - Lifetime CN1112926C (zh) | 1997-06-05 | 1998-06-02 | 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN02149972A Pending CN1430959A (zh) | 1997-06-05 | 2002-11-05 | 含有5－[4－[2－（n－甲基－n－2－吡啶基）氨基）乙氧基]苄基]噻唑烷－2，4－二酮的组合物 |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP0998284A1 (es) |
| JP (1) | JP2001521553A (es) |
| KR (1) | KR20010013410A (es) |
| CN (3) | CN1112926C (es) |
| AP (1) | AP1214A (es) |
| AR (2) | AR008198A1 (es) |
| AU (1) | AU8215098A (es) |
| BG (1) | BG104048A (es) |
| BR (1) | BR9810405A (es) |
| CA (2) | CA2292629C (es) |
| CO (1) | CO4940400A1 (es) |
| DZ (1) | DZ2510A1 (es) |
| EA (1) | EA002384B1 (es) |
| GB (1) | GB9711683D0 (es) |
| HU (1) | HUP0004070A3 (es) |
| ID (1) | ID24264A (es) |
| IL (1) | IL133074A0 (es) |
| MX (1) | MXPA99011322A (es) |
| NO (2) | NO995938L (es) |
| NZ (2) | NZ523725A (es) |
| OA (1) | OA11306A (es) |
| PE (1) | PE78899A1 (es) |
| PL (1) | PL337201A1 (es) |
| SK (1) | SK164899A3 (es) |
| TR (2) | TR200002790T2 (es) |
| TW (1) | TW570797B (es) |
| UY (1) | UY25032A1 (es) |
| WO (1) | WO1998055122A1 (es) |
| ZA (2) | ZA9811572B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20013800A3 (cs) * | 1999-04-23 | 2002-04-17 | Smithkline Beecham Plc | Polymorf soli 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]-benzyl]thiazolidin-2,4-dionu s kyselinou maleinovou |
| DE60004658T2 (de) | 1999-04-23 | 2004-06-24 | Smithkline Beecham Plc, Brentford | Thiazolidindionderivat und seine verwendung als antidiabetikum |
| US20040248945A1 (en) | 1999-04-23 | 2004-12-09 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| GB0021978D0 (en) | 2000-09-07 | 2000-10-25 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| GB0129876D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2003050112A1 (en) * | 2001-12-13 | 2003-06-19 | Smithkline Beecham Plc | Toluenesulfonate hydrates of a thiazolidinedione derivative |
| GB0129871D0 (en) * | 2001-12-13 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0130509D0 (en) * | 2001-12-20 | 2002-02-06 | Smithkline Beecham Plc | Novel pharmaceutical |
| US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
| DE06252444T8 (de) * | 2006-05-09 | 2009-03-19 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino)-ethoxy]-phenyl]-methyl]-2,4-thiazolidindion}-bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazonmaleat |
| WO2015008234A1 (en) * | 2013-07-17 | 2015-01-22 | Glenmark Pharmaceuticals S.A. | Bicyclic heterocyclic compounds as ror gamma modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE186724T1 (de) * | 1987-09-04 | 1999-12-15 | Beecham Group Plc | Substituierte thiazolidindionderivate |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| CN1083715C (zh) * | 1994-02-10 | 2002-05-01 | 史密丝克莱恩比彻姆有限公司 | 胰岛素敏化物治疗肾病的应用 |
| NZ313874A (en) * | 1995-08-10 | 2000-09-29 | Warner Lambert Co | Compounds used as medicaments useful in eliminating the amount of exogenous insulin administered to a patient having noninsulin-dependent diabetes mellitus |
| WO1997018811A1 (en) * | 1995-11-17 | 1997-05-29 | Warner-Lambert Company | A method of treating myotonic dystrophy |
| IL120443A (en) * | 1996-03-18 | 2000-07-16 | Sankyo Co | Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis |
| CN1230114A (zh) * | 1996-07-12 | 1999-09-29 | 史密丝克莱恩比彻姆有限公司 | Leptine抵抗的新疗法 |
-
1997
- 1997-06-05 GB GBGB9711683.4A patent/GB9711683D0/en active Pending
-
1998
- 1998-06-02 BR BR9810405-5A patent/BR9810405A/pt not_active IP Right Cessation
- 1998-06-02 CN CN98805686A patent/CN1112926C/zh not_active Expired - Lifetime
- 1998-06-02 WO PCT/EP1998/003478 patent/WO1998055122A1/en not_active Application Discontinuation
- 1998-06-02 SK SK1648-99A patent/SK164899A3/sk unknown
- 1998-06-02 JP JP50158799A patent/JP2001521553A/ja not_active Ceased
- 1998-06-02 MX MXPA99011322A patent/MXPA99011322A/es unknown
- 1998-06-02 PL PL98337201A patent/PL337201A1/xx unknown
- 1998-06-02 CN CNA2003101199090A patent/CN1526391A/zh active Pending
- 1998-06-02 TR TR2000/02790T patent/TR200002790T2/xx unknown
- 1998-06-02 NZ NZ523725A patent/NZ523725A/en unknown
- 1998-06-02 CA CA002292629A patent/CA2292629C/en not_active Expired - Fee Related
- 1998-06-02 EA EA199901116A patent/EA002384B1/ru not_active IP Right Cessation
- 1998-06-02 IL IL13307498A patent/IL133074A0/xx unknown
- 1998-06-02 HU HU0004070A patent/HUP0004070A3/hu unknown
- 1998-06-02 ID IDW991520A patent/ID24264A/id unknown
- 1998-06-02 KR KR19997011411A patent/KR20010013410A/ko not_active Application Discontinuation
- 1998-06-02 TR TR1999/02963T patent/TR199902963T2/xx unknown
- 1998-06-02 AP APAP/P/1999/001696A patent/AP1214A/en active
- 1998-06-02 AU AU82150/98A patent/AU8215098A/en not_active Abandoned
- 1998-06-02 CA CA002333352A patent/CA2333352A1/en not_active Abandoned
- 1998-06-02 EP EP98932144A patent/EP0998284A1/en not_active Withdrawn
- 1998-06-03 DZ DZ980120A patent/DZ2510A1/xx active
- 1998-06-04 AR ARP980102649A patent/AR008198A1/es not_active Application Discontinuation
- 1998-06-04 ZA ZA9811572A patent/ZA9811572B/xx unknown
- 1998-06-04 CO CO98031614A patent/CO4940400A1/es unknown
- 1998-06-04 UY UY25032A patent/UY25032A1/es not_active IP Right Cessation
- 1998-06-04 AR ARP980102650A patent/AR015120A1/es not_active Application Discontinuation
- 1998-06-04 ZA ZA9804826A patent/ZA984826B/xx unknown
- 1998-06-05 PE PE1998000466A patent/PE78899A1/es not_active Application Discontinuation
- 1998-10-23 TW TW087117536A patent/TW570797B/zh not_active IP Right Cessation
-
1999
- 1999-12-02 OA OA9900267A patent/OA11306A/en unknown
- 1999-12-03 NO NO995938A patent/NO995938L/no not_active Application Discontinuation
- 1999-12-27 BG BG104048A patent/BG104048A/bg unknown
-
2001
- 2001-09-03 NZ NZ513922A patent/NZ513922A/xx unknown
-
2002
- 2002-11-05 CN CN02149972A patent/CN1430959A/zh active Pending
-
2004
- 2004-02-20 NO NO20040738A patent/NO20040738L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1230171C (zh) | 用噻唑烷二酮和二甲双胍治疗糖尿病 | |
| CN1112926C (zh) | 含有5－[4－[2－(n－甲基－n－2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的组合物 | |
| CN1443068A (zh) | 用于治疗糖尿病的二肽基肽酶iv抑制剂和其它抗糖尿病药剂的组合用药物 | |
| CN1285831A (zh) | 取代的噻唑烷二酮衍生物,其制备过程及其药学用途 | |
| CN1133431C (zh) | 用罗西格列酮和胰岛素治疗糖尿病 | |
| CN1289081C (zh) | 改进释放的胰岛素致敏物的药用组合物 | |
| CN1212625A (zh) | 用于治疗呼吸系统疾病的咖啡因和氯马斯汀 | |
| CN1264303A (zh) | 用噻唑烷二酮、胰岛素促分泌剂和双胍治疗糖尿病 | |
| CN1168451C (zh) | 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途 | |
| CN1602206A (zh) | 含有氮杂环丁烷衍生物的药物组合物 | |
| CN1301162A (zh) | 控制肥胖的方法 | |
| CN1107707A (zh) | 抑制体重增加或诱发体重减轻的方法 | |
| CN1274282A (zh) | 用噻唑烷二酮和α－葡糖苷酶抑制剂治疗糖尿病 | |
| CN1263467A (zh) | 用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病 | |
| CN1642532A (zh) | 曲马多缓释制剂 | |
| CN1264302A (zh) | 用噻唑烷二酮和磺酰脲治疗糖尿病 | |
| CN1332638A (zh) | 包含β－激动剂和其它抗糖尿病药物的组合物 | |
| CN101066267A (zh) | 一种含有阿立哌唑微晶的固体口服药物组合物 | |
| CN1366520A (zh) | 新型医药 | |
| CN1167416C (zh) | 利用葡萄糖摄入增强剂制备减小心脏缺血后损伤的药物 | |
| CN1235586C (zh) | 改进释放组合物及其用途 | |
| CN1883480A (zh) | 一种含卢帕他定的药物组合物 | |
| CN1868477A (zh) | 一种盐酸雷诺嗪制剂配方 | |
| CN100345846C (zh) | 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮的钠盐 | |
| CN1443186A (zh) | 用于糖尿病治疗的噻唑烷二酮盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |